ZYMEWORKS INC. Financing Cash Flow
ZYMEWORKS INC. (ZYME) reported Financing Cash Flow of $128.77 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- ZYMEWORKS INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$50.02M, a 3892.19% decline year-over-year.
- ZYMEWORKS INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $178.79M, a 13485.56% increase year-over-year.
- ZYMEWORKS INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was -$18.74M.
- ZYMEWORKS INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$2.45M.
- ZYMEWORKS INC. net cash provided by (used in) financing activities for fiscal 2025 was -$18.56M.
- ZYMEWORKS INC. net cash provided by (used in) financing activities for fiscal 2024 was -$20.44M, a 124.96% decline from fiscal 2023.
- ZYMEWORKS INC. net cash provided by (used in) financing activities for fiscal 2023 was $81.87M, a 24.60% decline from fiscal 2022.
- ZYMEWORKS INC. net cash provided by (used in) financing activities for fiscal 2022 was $108.58M, a 1255.41% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 3 month as first filed | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 6 month as first filed | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 9 month as first filed | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$50.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $128.77M 10-Q · filed 2026-08-06 | $110.03M derived: sum of 3 quarters · filed 2026-08-06 | $107.57M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $178.79M 10-Q · filed 2026-05-07 | $160.04M derived: sum of 2 quarters · filed 2026-05-07 | $157.59M derived: sum of 3 quarters · filed 2026-05-07 | $158.91M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | -$18.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$21.19M derived: sum of 2 quarters · filed 2026-03-02 | -$19.88M derived: sum of 3 quarters · filed 2026-08-06 | -$18.56M 10-K · filed 2026-03-02 | ||||
| 2025-09-30 | -$2.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$1.13M derived: sum of 2 quarters · filed 2026-08-06 | $183.00K 10-Q · filed 2025-11-06 | -$8.46M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $1.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.63M 10-Q · filed 2026-08-06 | -$6.01M derived: sum of 3 quarters · filed 2026-08-06 | -$20.98M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $1.32M 10-Q · filed 2026-05-07 | -$7.33M derived: sum of 2 quarters · filed 2026-05-07 | -$22.30M derived: sum of 3 quarters · filed 2026-05-07 | -$21.25M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | -$8.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$23.62M derived: sum of 2 quarters · filed 2026-03-02 | -$22.57M derived: sum of 3 quarters · filed 2026-03-02 | -$20.44M 10-K · filed 2026-03-02 | -$20.45M 10-K · filed 2025-03-05 | |||
| 2024-09-30 | -$14.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$13.93M derived: sum of 2 quarters · filed 2025-11-06 | -$11.80M 10-Q · filed 2025-11-06 | -$11.81M 10-Q · filed 2024-10-31 | $38.84M derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2024-06-30 | $1.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $3.18M 10-Q · filed 2025-08-07 | $3.17M 10-Q · filed 2024-08-01 | $53.81M derived: sum of 3 quarters · filed 2026-03-02 | $55.71M derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2024-03-31 | $2.13M 10-Q · filed 2025-05-08 | $2.12M 10-Q · filed 2024-05-02 | $52.76M derived: sum of 2 quarters · filed 2026-03-02 | $54.66M derived: sum of 3 quarters · filed 2026-03-02 | $82.26M derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2023-12-31 | $50.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $52.53M derived: sum of 2 quarters · filed 2026-03-02 | $80.13M derived: sum of 3 quarters · filed 2026-03-02 | $81.87M 10-K · filed 2026-03-02 | $81.85M 10-K · filed 2024-03-06 | |||
| 2023-09-30 | $1.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $29.50M derived: sum of 2 quarters · filed 2024-10-31 | $31.24M 10-Q · filed 2024-10-31 | $30.86M derived: sum of 4 quarters · filed 2025-03-05 | ||||
| 2023-06-30 | $27.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $29.34M 10-Q · filed 2024-08-01 | $28.96M derived: sum of 3 quarters · filed 2025-03-05 | $29.59M derived: sum of 4 quarters · filed 2025-03-05 | ||||
| 2023-03-31 | $1.74M 10-Q · filed 2024-05-02 | $1.36M derived: sum of 2 quarters · filed 2025-03-05 | $1.99M derived: sum of 3 quarters · filed 2025-03-05 | $1.71M derived: sum of 4 quarters · filed 2025-03-05 | ||||
| 2022-12-31 | -$377.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $251.00K derived: sum of 2 quarters · filed 2025-03-05 | -$28.00K derived: sum of 3 quarters · filed 2025-03-05 | $108.58M 10-K · filed 2025-03-05 | ||||
| 2022-09-30 | $628.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $349.00K derived: sum of 2 quarters · filed 2023-11-07 | $108.96M 10-Q · filed 2023-11-07 | $109.65M derived: sum of 4 quarters · filed 2024-03-06 | ||||
| 2022-06-30 | -$279.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $108.33M 10-Q · filed 2023-08-10 | $109.02M derived: sum of 3 quarters · filed 2024-03-06 | |||||
| 2022-03-31 | $108.61M 10-Q · filed 2023-05-08 | $109.30M derived: sum of 2 quarters · filed 2024-03-06 | ||||||
| 2021-12-31 | $689.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $8.01M 10-K · filed 2024-03-06 | ||||||
| 2021-09-30 | $7.32M 10-Q · filed 2022-11-08 | |||||||
| 2020-12-31 | $308.98M 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |